For chronic pain sufferers, there is a real problem with the abuse of painkillers in the United States. While the number of patients who have a legitimate need for prescription painkillers — 100 million plus — is vastly more than the number of people addicted to painkillers — 11 million — there is a stigma attached to the prescribing, dispensing and utilization of pain medicines.
News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.
RetireSafe, a grassroots organization advocating on behalf of America’s seniors on Tuesday released a survey finding that seniors overwhelmingly support strong patient safeguards for biosimilar medications.
Giant Eagle last week added prescription blood-pressure medications lisinopril and lisinopril HCTZ to the list of several antibiotics that the chain provides for free to its patients, according to a report inthe Columbus Dispatch.
Although the pace of approvals for new orphan drugs — medicines that treat relatively rare conditions — have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study released last week by the Tufts Center for the Study of Drug Development at Tufts University has concluded.
Anacor Pharmaceuticals announced that the Food and Drug Administration has approved the company's new drug application for Kerydin (tavaborole) topical solution, 5% — an antifungal approved for the topical treatment of onychomycosis of the toenails.
America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report released by the Pharmaceutical Research and Manufacturers of America last week.
As healthcare decision-makers grapple with how to ensure access to specialty medications, the University of Michigan Center for Value-Based Insurance Design and the National Pharmaceutical Council on Monday released a new report, "Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design," which explores how value-based insurance design could be utilized to address specialty medication access concerns.
There may be a connection between taking vasodilators and developing early-stage, age-related macular degeneration, the leading cause of vision loss and blindness among Americans who are ages 65 and older, according to a study published online Wednesday in Ophthalmology, the journal of the American Academy of Ophthalmology.
About half of all Americans reported taking one or more prescription drugs in the past 30 days during 2007-2010, and 1-in-10 took five or more, according to "Health, United States, 2013," the government’s annual, comprehensive report on the nation’s health that was released Wednesday.
AstraZeneca on Tuesday announced the Food and Drug Administration approved Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).
U.S. pharmaceutical firm Pfizer this morning confirmed discussions with AstraZeneca regarding a possible merger. If the transaction goes through, it's expected that the two companies will combine under a new U.K-incorporated holding company.
The Generic Pharmaceutical Association has announced its support of the U.S. Drug Enforcement Administration’s eighth annual National Prescription Drug Take-Back Day, taking place April 26 at local take-back sites across America.
More Americans are more often seeking their ounce of prevention. According to Bain & Co.’s recent Healthy Living Survey, 75% of consumers are in pursuit of a healthier lifestyle. Take that predominant mindset, coupled with the outcomes-driven preventive focus associated with the Affordable Care Act, and you have a formula for OTC success at retail pharmacy.